Shares of Ingevity Corporation (NYSE:NGVT – Get Free Report) have been given a consensus rating of “Hold” by the five analysts that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $80.00.
A number of analysts have weighed in on NGVT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a report on Tuesday, April 21st. Wall Street Zen cut shares of Ingevity from a “strong-buy” rating to a “buy” rating in a report on Monday.
Read Our Latest Report on NGVT
Ingevity Stock Performance
Ingevity (NYSE:NGVT – Get Free Report) last released its earnings results on Wednesday, May 6th. The company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.84 by $0.31. The firm had revenue of $258.00 million during the quarter, compared to analyst estimates of $254.73 million. Ingevity had a negative net margin of 10.55% and a positive return on equity of 207.82%. The firm’s revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.01 earnings per share. Ingevity has set its FY 2026 guidance at 4.700-5.200 EPS. As a group, equities research analysts predict that Ingevity will post 5.05 EPS for the current year.
Insider Buying and Selling at Ingevity
In related news, SVP Terrance M. Dyer sold 496 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $68.49, for a total transaction of $33,971.04. Following the completion of the transaction, the senior vice president directly owned 7,202 shares in the company, valued at $493,264.98. This represents a 6.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.88% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in NGVT. Global Retirement Partners LLC bought a new position in Ingevity during the 4th quarter worth $27,000. Meeder Asset Management Inc. bought a new position in Ingevity during the 4th quarter worth $33,000. Geneos Wealth Management Inc. grew its stake in Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock worth $36,000 after buying an additional 387 shares during the last quarter. Headlands Technologies LLC bought a new position in Ingevity during the 2nd quarter worth $46,000. Finally, Kestra Advisory Services LLC bought a new position in Ingevity during the 4th quarter worth $47,000. 91.59% of the stock is currently owned by institutional investors.
Ingevity Company Profile
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Featured Stories
- Five stocks we like better than Ingevity
- NextEra’s Dominion Deal Could Put It at the Center of the AI Power Race
- Amazon Could Be About to Reap the Rewards of a Software Spending Boom
- Best Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs Proof
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
